| INTRODUCTION
C-peptide indices are utilized to assess the loss of insulin secretion prior to and after the diagnosis of type 1 diabetes (T1D) in both clinical and research contexts. Clinically, these measures are used to differentiate T1D from type 2 diabetes and in guiding therapy. In addition, particularly in the United States, insurers have used Cpeptide thresholds for determining whether insulin pumps and sensors should be covered. In the research setting, C-peptide measures are used to examine patterns of insulin loss in natural history studies, 1 and as entry criteria and endpoints in clinical trials assessing interventions intended to prevent insulin loss. [2] [3] [4] [5] [6] [7] In examining β-cell function for these purposes, it is essential to minimize other factors that could influence C-peptide levels apart from the pathology that is specific to T1D. Such factors include adiposity and age. Adiposity is known to be associated with insulin resistance. 8, 9 Although the direct influence of age on insulin resistance is less certain, 10 age could influence insulin secretion by other mechanisms, such as possibly influencing β-cell mass. 11 Thus, it is important to characterize the associations of C-peptide measures with indicators of adiposity such as body mass index (BMI) and age at the diagnosis of T1D to avoid a misinterpretation of β-cell function.
Since there is little information available regarding associations of C-peptide with BMI and age at the diagnosis of T1D, we have utilized Diabetes Prevention Trial-Type 1 (DPT-1) data to study the influence of BMI and age on C-peptide at the time of and soon after the diagnosis of T1D. In the DPT-1 study, a number of individuals were diagnosed by oral glucose tolerance testing which included C-peptide determinations. The findings presented below provide information that is relevant to assessments of β-cell function in both clinical and research settings.
| METHODS

| Subjects
Subjects who participated in the parenteral 12 and oral 13 insulin DPT-1 trials have previously been described in detail. All of the participants had islet cell autoantibodies and all were related to patients with T1D; neither the parenteral nor the oral insulin interventions showed efficacy. All participants included in the analysis were <18.0 years of age at diagnosis. 
| Procedures
As previously described, 12, 13 in both the parenteral and oral insulin DPT-1 trials, OGTTs were originally performed at 6-month (AE3 
| Laboratory measures
Plasma glucose levels were measured by the glucose oxidase method.
C-peptide levels were measured by radioimmunoassay. Fasting Cpeptide values in the undetectable range (<0.2 ng/mL) were assigned a value of 0.1 ng/mL for the analyses. Three C-peptide measures were analyzed: fasting, area under the curve (AUC), and the 30 to 0-minute difference. The latter was included in the analysis, since it correlates with the first phase insulin response and declines during the latter stages of progression to T1D. 14 The same C-peptide measures were used for the OGTT and MMTT analyses.
| Data analysis
Each of the analysis cohorts (OGTT and MMTT) was characterized using summary statistics, and two-sample t tests and chi-square tests were used to compare factors and measures between groups of interest. Univariate and multivariable generalized linear regression models were used to examine associations of C-peptide variables with BMIZ and age. Models for each of the analysis cohorts were evaluated that adjusted for BMIZ alone, age alone, and for both. Pearson correlations were also utilized. Exploratory analyses supported the use of untransformed C-peptide measures; in addition, associations were similar when C-peptide values were log-transformed.
To illustrate and further evaluate the influence of BMIZ and age on AUC C-peptide, coefficients for BMIZ and age for each of these fitted models were used to calculate an adjusted AUC C-peptide estimate from OGTTs at diagnosis and MMTTs after diagnosis. The influence of removing subject-specific BMIZ and age-related effects on AUC C-peptide was assessed by subtracting the subject-specific effects for BMIZ and age, according to the fitted models, from the actual observed AUC C-peptide value. We explored this delineation of effects added to the estimated AUC C-peptide that were specific to BMIZ and/or age for the individual difference from the average subject. In this context, those in the extremes for BMIZ or age in relation to the average cohort subject will have a greater adjustment to their AUC C-peptide than those whose BMIZ or age is near the overall average. An example of the formulaic approach for this functional adjustment is:ỹ
where For the figure, data were categorized according to tertiles; comparisons were made between the highest and lowest groups. OGTT and MMTT AUCs were calculated with the trapezoidal rule. The SAS (SAS Institute; Cary, NC). 9.2 version was used for the analyses. All Pvalues are two-sided with a significance level set at .05.
| RESULTS
There were 99 DPT-1 participants with OGTTs at diagnosis (mean AE SD age at diagnosis: 11.3 AE 3.3 years; mean AE SD BMIZ at diagnosis:
0.42 AE 1.13; 58% male) who were analyzed. Also, 80 DPT-1 participants were analyzed who had MMTTs within 6 months after diagnosis (age at MMTT: 11.8 AE 3.4 years; BMIZ at MMTT: 0.52 AE 1.08; 53% male). Characteristics of the participants are shown in Table 1 and values of C-peptide indices from the OGTTs and MMTTs are shown in Table 2 . There were no differences between male and female participants in any of the C-peptide measures among the OGTT (male: n = 57; female: n = 42; P ≥ .78 for differences) and the MMTT (male: n = 38; female: n = 42; P ≥ .28 for differences) cohorts.
Regression coefficients for the associations of fasting C-peptide, 30 to 0-minute C-peptide difference, and AUC C-peptide from the OGTTs and MMTTs with BMIZ and age are shown in Table 3 . There were substantial positive associations of the fasting and AUC Cpeptide from the OGTTs with BMIZ and with age (P < .001 for both).
However, the 30 to 0-minute C-peptide difference was not significantly associated with BMIZ or with age.
The associations of the fasting and AUC C-peptide from the MMTTs with BMIZ and with age were also positive and significant (P < .001 for all). Their magnitudes were similar to those for the OGTT associations. However, in contrast to the OGTTs, there was also a significant association of the 30 to 0-minute C-peptide difference with BMIZ (P < .05). There were no significant associations of any of the C-peptide measures from the OGTTs or the MMTTs with gender. Figure 1 shows C-peptide values for each OGTT time point according to BMIZ and age tertiles. The C-peptide values were significantly greater for the highest BMIZ tertile than for the lowest tertile at all OGTT time points (P < .01 for all). The differences were even greater between the highest and lowest age tertiles (P < .001 at all the OGTT time points). For BMIZ, the values of the middle tertile were slightly higher than the values of the lowest tertile, whereas for age the values of the middle tertile were closer to the highest tertile. Table 4 shows data from regression models with the C-peptide indices of the OGTTs and MMTTs as dependent variables, and BMIZ and age for oral glucose tolerance tests (OGTTs, n = 99) at diagnosis and for mixed meal tolerance tests (MMTTs) within 0.5 years after diagnosis 
FIGURE 1
Shown are mean area under the curve (AUC) C-peptide levels during oral glucose tolerance tests (OGTTs) according to body mass index Z-scores (BMIZ) and age tertiles. Those in the highest tertiles of BMIZ and age had markedly higher AUC C-peptide levels than those in the lowest tertiles. For BMIZ, the values of the middle tertile were slightly higher than the values of the lowest tertile, whereas for age the values of the middle tertile were closer to the highest tertile. The ages of those in the middle BMIZ tertile (10.6 AE 3.2 years) tend to be lower than the ages of those in the lowest 11.4 AE 3.6 and highest 11.8 AE 3.1 tertiles. After an adjustment for age, the AUC C-peptide values of the middle BMIZ tertile moved further from the lowest tertile (from 13% of the difference between the highest and lowest tertiles to 28% of the distance) and age included together as independent variables for each model.
Fasting and AUC C-peptide levels were significantly related to BMIZ and age in each model for both OGTTs and MMTTs. The R 2 (the proportion of the variance explained by BMIZ and age together in the models) for the associations of the fasting and AUC C-peptide with BMIZ and age varied from 0.31 to 0.47 for the OGTTs and MMTTs.
Notable were the similarities of the multivariable coefficients in Table 4 to the univariate coefficients in Table 3 . These findings indicate that the associations with BMIZ and age were largely independent of each other.
To demonstrate the extent of influence of BMIZ and age on C- We examined the extent to which BMIZ and age influenced the impact of C-peptide on glycemia at diagnosis. Whereas there was a significant association of fasting glucose values (log-transformed) with unadjusted fasting C-peptide levels (r = 0.30, P < .01), there was little association when fasting C-peptide levels were adjusted for BMIZ and age (r = −0.07, n.s.). There were significant associations of AUC glucose with both unadjusted and adjusted AUC C-peptide levels;
however, the association tended to be stronger (negatively) with adjusted AUC C-peptide levels (r = −0.37, P < .001 for adjusted; r = −0.30, P < .01 for unadjusted).
| DISCUSSION
The findings showed that at the diagnosis of T1D, an appreciable proportion of the variance of the fasting and AUC C-peptide from
OGTTs was explained by BMIZ and age. Notably, the associations of the C-peptide indices with BMIZ and age were independent of each other in multivariable models. When the AUC C-peptide was adjusted for BMIZ and/or age, the C-peptide values differed markedly from the actual values.
There is an appreciable loss of C-peptide after diagnosis. 15, 16 Since MMTTs occurred on average about 3 months after the OGTTs, it appears that despite the loss of C-peptide after diagnosis, the magnitude of the association of C-peptide with BMIZ and age persists.
The independence of BMIZ and age in their associations with the C-peptide indices suggests that the basis for the associations differs between BMIZ and age. Evidence from prior studies is consistent with this finding. Whereas studies have consistently shown associations between insulin resistance and indicators of the degree of adiposity such as BMI in other populations, 8, 9 the relationship of insulin resistance with age is less certain. 10 Since some β-cell characteristics are associated with age, 11, 17 it is possible that insulin secretion might be better sustained in older individuals who develop T1D. Age has been shown to be a mitigating factor for the risk of T1D 18 and for the loss of C-peptide levels soon after diagnosis. 16 The associations of C-peptide with BMIZ and age are clinically relevant, since C-peptide measurements are sometimes used to help to differentiate the types of diabetes at diagnosis and to guide therapy. Also, low C-peptide values have been used as a criterion for providing insurance coverage of insulin pumps and glucose sensors.
Thus, overweight and older children recently diagnosed with T1D Regression coefficients from models that included C-peptide indices as dependent variables with body mass index Z-scores (BMIZ) and age as independent variables for oral glucose tolerance tests (OGTTs) at diagnosis and for mixed meal tolerance tests (MMTTs) within 0.5 years after diagnosis Since adjustments of C-peptide for BMIZ and age essentially exclude the portion of C-peptide that is attributable to those characteristics, we examined differences between unadjusted and adjusted C-peptide values with regard to their associations with glucose values. The analysis showed that the positive association between the fasting glucose and fasting C-peptide was especially impacted by the adjustment, indicating that the association was almost fully attributable to BMIZ and age. The adjustment of the AUC C-peptide resulted in a stronger inverse association with the AUC glucose, but the impact was smaller.
Despite the substantial impact of BMIZ and age on C-peptide values, adjustments might not always be warranted. For example, adjustments for age could obscure the reasonable possibility that β-cell compromise is less severe at the diagnosis of T1D in older individuals. Thus, for natural history studies of β-cell decline, age stratification might be more appropriate than age adjustment. As more is learned about the bases for the associations of C-peptide with BMIZ and age, decisions regarding the need for adjustment can be made with more certainty.
The adjustments demonstrating the extent to which BMIZ and age influenced C-peptide levels do not necessarily generalize to other populations, since the coefficients for the associations could differ among populations. However, similar modeling procedures for adjustments could be utilized.
One of the limitations of the study was the lack of assessment of insulin resistance. We chose not to use indirect measures such as Homeostatic Model Assessment (HOMA-IR). as they have not been validated in newly diagnosed T1D patients. In addition, since pubertal status was not ascertained at the time of diagnosis, we could not determine the extent of association between C-peptide indices and puberty.
Insulin resistance has been shown to be associated with puberty. 8 As a result of OGTT surveillance, it is likely that the diagnosis in DPT-1 occurred earlier than the typical diagnosis made clinically. Thus, the associations are not necessarily indicative of those at the time of a clinical diagnosis. Finally, since the analyses were cross-sectional, inferences could not be made on β-cell decline.
No prior studies have examined the impact of BMIZ and age on C-peptide indices from OGTTs at diagnosis, including their impact on associations between glucose and C-peptide. Recent studies 19, 20 found that random C-peptide levels at diagnosis were higher in children with a greater degree of adiposity, and in older children. In a DPT-1 analysis, a correlation was observed between the AUC C-peptide from MMTTs and age in individuals at risk for T1D. 21 A study of children and adult T1D patients within 3 months of their diagnosis found positive associations of the AUC C-peptide from MMTTs with BMIZ and age. 16 In conclusion, the findings indicate that BMIZ and age substantially and independently influence C-peptide levels at and soon after the diagnosis of T1D. These associations should be considered in both clinical and research settings. Although adjustments for BMIZ and age can add clarity to assessments of β-cell function, they should only be undertaken after determining their appropriateness for a particular objective.
